Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Seeking Alpha / 1 Views

Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU

Comments